RICHMOND, British Columbia, Feb. 11, 2010 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX), a biotechnology company developing products based on patented technology in the areas of cancer diagnostics, today announced that it has launched the commercialization of its OncoPet RECAF test for cancer detection in dogs. The test detected 85 percent of a variety of cancers in dogs, at the standard 95 percent specificity level in pre-market studies. The Company believes that this launch represents the first commercialization of a blood-based test for the universal detection of cancer in companion animals. The test detects the presence of RECAF, a universal marker for malignant cell growth in humans and animals. BioCurex developed and patented the RECAF technology for cancer applications.
